Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Translations
    • Topics A-Z
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Translations
    • Topics A-Z
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • Practice Current
  • Practice Buzz

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Clinical Practice
Home
A peer-reviewed clinical neurology journal for the practicing neurologist
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues
  • Practice Current
  • Practice Buzz

Share

August 2021; 11 (4) ReviewOpen Access

Multiple Sclerosis Phenotypes as a Continuum

The Role of Neurologic Reserve

Timothy L. Vollmer, Kavita V. Nair, Ian M. Williams, Enrique Alvarez
First published January 29, 2021, DOI: https://doi.org/10.1212/CPJ.0000000000001045
Timothy L. Vollmer
Department of Neurology (TLV, KVN, EA), University of Colorado, and Rocky Mountain Multiple Sclerosis Center at the University of Colorado, Aurora; Department of Clinical Pharmacy (KVN), Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora; and Oxford PharmaGenesis (IMW), United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kavita V. Nair
Department of Neurology (TLV, KVN, EA), University of Colorado, and Rocky Mountain Multiple Sclerosis Center at the University of Colorado, Aurora; Department of Clinical Pharmacy (KVN), Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora; and Oxford PharmaGenesis (IMW), United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian M. Williams
Department of Neurology (TLV, KVN, EA), University of Colorado, and Rocky Mountain Multiple Sclerosis Center at the University of Colorado, Aurora; Department of Clinical Pharmacy (KVN), Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora; and Oxford PharmaGenesis (IMW), United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Enrique Alvarez
Department of Neurology (TLV, KVN, EA), University of Colorado, and Rocky Mountain Multiple Sclerosis Center at the University of Colorado, Aurora; Department of Clinical Pharmacy (KVN), Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora; and Oxford PharmaGenesis (IMW), United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Multiple Sclerosis Phenotypes as a Continuum
The Role of Neurologic Reserve
Timothy L. Vollmer, Kavita V. Nair, Ian M. Williams, Enrique Alvarez
Neurol Clin Pract Aug 2021, 11 (4) 342-351; DOI: 10.1212/CPJ.0000000000001045

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
2085

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1 Inflammatory Activation in Early MS Leads to Astrocyte Activation, Demyelination, and Neuronal Destruction

    (A) The dura mater and subarachnoid space of the brain are well connected to the circulation, filled with blood vessels and lymphatic vessels across which immune cells, such as B and T lymphocytes, can enter and exit the CNS. (B) Autoreactive B cells and T cells mature in the lymph nodes, including the deep cervical lymph nodes, and enter the circulation, where (C) these cells cross the blood-brain barrier and enter the CNS. Effector functions of autoreactive B cells include antibody and cytokine production, and antigen presentation to T cells, which further drives CNS inflammation. The proinflammatory cytokines released by these cells drive the activation of CNS resident cells, including astrocytes.e49 The inflammatory processes mediated by activated astrocytes include the release of TNF-α, production of reactive oxygen species including NO (via iNOS) and other toxic intermediates, leading to oligodendrocyte damage and apoptosis, neuronal/axonal damage, and the loss of astrocytes themselves. Oligodendrocyte damage may be compounded by the fact that some patients with MS can be predisposed to factors that inhibit oligodendrocyte maturation,3 and loss of normal astrocyte function may also affect the blood-brain barrier, microglial activation, and neuronal damage. Indeed, repair in lesions is accompanied not only by regeneration of oligodendrocytes but the reappearance and maturation of astrocytes. Of interest, the role of astrocytes was elucidated by studies with the S1PRm fingolimod. S1PRms are also thought to be potentially neuroprotective in the CNS through their direct effects on astrocytes, as well as neurons and oligodendrocytes.e49 Autoreactive B cells are able to leave the CNS, crossing the blood-brain barrier by draining through the deep cervical lymph nodes and on into the peripheral lymphatic system, where further rounds of maturation and clonal expansion can occur before repopulating the CNS and driving pathologic process further. iNOS = inducible nitric oxide synthase; NO = nitric oxide; S1PRm = sphingosine-1 phosphate receptor modulator; TNF = tumor necrosis factor.

  • Figure 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2 The Concept of Brain/Neurologic Reserve in MS32,33

    (A) Cross-sectional relationships between components of reserve and performance. This model provides a roadmap for the nomenclature and expected relationships among reserve-related constructs at a specific point in time. Going counterclockwise from left, genetic and inborn factors refer to inborn or background determinants of brain function (e.g., single nucleotide polymorphisms). These factors are the only direct causes of (innate) brain reserve, which represents a patient's potential brain structure (e.g., head size, intracranial volume, synapse count, and CNS structure). Regardless of a patient's brain reserve, the patient's neuronal network function represents the present level of functioning of a patient (e.g., functional connectivity as measured by functional magnetic resonance imaging). Then, the combination of a patient's present neuronal network function, environmental factors (e.g., socioeconomic adversity or advantage and stressful events), and disease burden (e.g., diagnosis, symptoms, treatment side effects, and progressive disability) determines the patient's expected performance on a task. Finally, the difference between observed and expected performance is affected by the person's expected performance, (acquired) reserve and reserve-related person characteristics. Reserve and reserve-related person characteristics are each hypothesized to lead to larger differences between observed and expected performance, but through different mechanisms. Whereas reserve relates specifically to compensatory or protective brain function, reserve-related person characteristics refer to attitudes, values, or socioemotional skills that are posited to enhance an individual's resilience in the face of adversity and/or disease. Both reserve and reserve-related person characteristics are posited to be directly affected by the individual's past and current reserve-building activities. Such activities are hypothesized to include a multidimensional array of activities that promote brain health, including cultural/intellectual pursuits, physical activity, social/community participation, spiritual/religious practices, and dietary/lifestyle habits. (B) Brain reserve as a function of normal aging and in MS. In healthy people, brain reserve is initially high, but slowly declines as people age. Only at advanced ages would cognitive/brain health be affected by the loss of brain reserve. In people with MS, brain reserve can initially buffer/compensate for the effects of disease (preclinical phase). However, in MS, brain reserve is depleted more rapidly by the effects of aging and disease processes. Brain reserve is lowered to a level at which it can no longer compensate and the impact of disease on cognitive/brain health becomes apparent, manifesting as disease progression. (C) As described above, brain reserve buffers/slows disease progression. Patients with lower levels of brain reserve may progress through all the classically defined stages of disease progression, with overt “unbuffered” symptoms at each stage that are easily diagnosed (top line). Those with intermediate levels of brain reserve may appear asymptomatic for longer, with the disease progressing in the background before the loss of reserve manifests as overt relapsing-remitting symptoms before progressive disease (middle line). Patients with very high brain reserve may appear functionally asymptomatic even while the clinical effects of the relapsing phase are ongoing, buffered until disease processes overcome reserve and manifest overtly as primary progressive disease (bottom line). MS = multiple sclerosis. Adapted from (A) Schwartz et al., 2016.33

  • Figure 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3 Rates of Brain Atrophy in MS and in Normal Aging and Rates of Disability Worsening in RRMS and SPMS35,38

    Stacked histograms showing the trend of brain atrophy slopes by age in HCs (red) and MS-specific atrophy (blue). The total rate of atrophy in patients with MS is represented by the total height of each histogram bar (combining colors). For SIENA (A) and the thalamus (B), the contribution of MS-specific atrophy and normal aging to the total atrophy slope changed significantly across decades, whereas normal aging was stable across decades in the caudate (C) and the putamen (D). The rates of disability worsening in RRMS and SPMS are depicted in (E), in which mean annualized EDSS scores indicate that disability worsening is significantly higher in patients with SPMS in the first 3 years after initiating treatment than in those with RRMS. Data are annualized to allow comparison between time epochs of different duration. *p < 0.5, **p < 0.01, ***p < 0.001, Mann-Whitney U test. EDSS = Expanded Disability Status Scale; HC = healthy control; MS = multiple sclerosis; RRMS = relapsing-remitting MS; SIENA = structural image evaluation using normalization of atrophy; SPMS = secondary progressive MS. Adapted from (A–D) Azevedo et al., 2019,35 and (E) Coles et al., 2006.38

Tables

  • Figures
  • Table 1
  • Table 2
  • Table

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Is There Evidence That Progressive and Relapsing MS Are Distinct Conditions?
    • What Does Explain the Different MS Phenotypes?
    • Reducing MS Comorbidities and Protecting Neurologic Reserve Through Diet and Physical Activity
    • Pharmacologic Treatment of PrMS: What Do Clinical Trial Results Suggest?
    • Conclusions
    • Study Funding
    • Disclosure
    • Appendix Authors
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Safety and Efficacy of Tenecteplase and Alteplase in Patients With Tandem Lesion Stroke: A Post Hoc Analysis of the EXTEND-IA TNK Trials

Dr. Nicole Sur and Dr. Mausaminben Hathidara

► Watch

Related Articles

  • Loss of Neurologic Reserve in Progressive Multiple SclerosisA Paradigm Shift?

Topics Discussed

  • All Genetics
  • All Clinical Neurology
  • Multiple sclerosis
  • MRI

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Review
    Secondary Progressive Multiple Sclerosis
    New Insights
    Bruce A.C. Cree, Douglas L. Arnold, Jeremy Chataway et al.
    Neurology, June 04, 2021
  • Views & Reviews
    Defining the clinical course of multiple sclerosis
    The 2013 revisions
    Fred D. Lublin, Stephen C. Reingold, Jeffrey A. Cohen et al.
    Neurology, May 28, 2014
  • Views & Reviews
    Serum neurofilament light as a biomarker in progressive multiple sclerosis
    Raju Kapoor, Kathryn E. Smith, Mark Allegretta et al.
    Neurology, July 16, 2020
  • Articles
    Familial effects on the clinical course of multiple sclerosis
    A. E. Hensiek, S. R. Seaman, L. F. Barcellos et al.
    Neurology, January 29, 2007
Neurology: Clinical Practice: 13 (4)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Clinical Practice |  Print ISSN: 2163-0402
Online ISSN: 2163-0933

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise